Of the 12 patients studied prospectively six had initial serum phenytoin concentrations below 15 ,tg./ml.; none of these had symptoms or signs suggestive of phenytoin toxicity. All but one of the remainder had some gum hypertrophy and this was of moderate degree in the patient with the highest initial value, 51 ,ug./ml. Nystagmus was induced in one patient who had a serum concentration of 40 ,ug./ml. Three others were reported to show slight apathy.
Of the 12 patients studied prospectively six had initial serum phenytoin concentrations below 15 ,tg./ml.; none of these had symptoms or signs suggestive of phenytoin toxicity. All but one of the remainder had some gum hypertrophy and this was of moderate degree in the patient with the highest initial value, 51 ,ug./ml. Nystagmus was induced in one patient who had a serum concentration of 40 ,ug./ml. Three others were reported to show slight apathy.
Reduction in frequency of fits was not related to the increase in the mean phenytoin concentration within this group, but the relatively short period of study reduced the sensitivity of the test.
Discussion
Wide and unpredictable variation in the serum concentrations of phenytoin at first cast doubt on our methods of extraction and estimation of the drug. There was, however, no apparent source of important error; duplicate measurements under blind conditions gave reproducible results, standards in a variety of sera gave consistent readings, the absorption spectra of standards and samples were similar, and no extract from the pooled sera used for blank estimations produced an absorption band with a peak at 235 m,u.
Confidence in our techniques was restored when a consistent pattern emerged between the results of the four groups of patients examined. The initial concentration of phenytoin among those studied prospectively was similar to that of the other outpatients: 17.5 and 15.7 ,ug./ml. respectively (see Table) . In contrast, at the end of the period of modified supervision the mean concentration among the outpatients had risen to approach that of the inpatients: 27.7 and 28.0 ,ug./ml. respectively. The tendency for those patients with low initial phenytoin concentrations to show large increments during the study supports the interpretation that they were encouraged to take their drugs as prescribed. Moreover, the mean concentration attained suggests that a high degree of co-operation was achieved within the group and that the remaining disparity in serum concentrations between patients is due largely to factors other than dosage. Two inpatients and two outpatients taking only 100 mg. of phenytoin daily provided samples containing more than 30 ,g./ml. None of the patients on the prescribed doses of 200 or 300 mg. per day attained higher concentrations, but in no instance did the concentration remain below 10 ,ug./ml. It is likely that for most patients a serum concentration of 10 to 20 ,g. of phenytoin per ml. has a therapeutic effect (Buchthal et al., 1960; Kutt and McDowell, 1968) . Some patients can maintain this concentration on a dose of 100 mg./day, others either absorb the drug less efficiently or eliminate it more rapidly (Kutt et al., 1966 Summary: The plasma glucose and blood pyruvate levels were determined after oral glucose tolerance test in six groups of women: non-obese and obese controls and in non-obese and obese women receiving glucocorticoid or oral contraceptive therapy. The mean fasting plasma glucose level was similar in all groups, but glucose tolerance was impaired in the obese controls, non-obese women on oral contraceptives or being treated with glucocorticoids, and appreciably impaired in the obese oral contraceptive and glucocorticoid groups compared with mean levels in non-obese subjects of the same groups.
Obesity was associated with abnormally raised blood pyruvate levels in response to a glucose tolerance test in all groups. Striking similarities were observed between the responses of the plasma glucose and blood pyruvate levels to glucose tolerance tests in the obese control and nonobese oral contraceptive and non-obese glucocorticoidtreated groups. It is suggested that these abnormalities result from a comnmon mechanism-namely, glucocorticoid excess.
Introduction
Impaired oral (Gershberg et al., 1964; Doar, 1966, 1969) and intravenous glucose tolerance (Wynn and Doar, 1966; Posner et al., 1967a Posner et al., , 1967b have been noted during oestrogen-progestogen therapy, but the mechanism of these changes has not been elucidated. The finding of abnormally raised blood pyruvate levels, both fasting and after glucose administration, led us to suggest that the chemical diabetes occurring during oral contraceptive therapy was " steroid diabetes," resulting from raised plasma cortisol levels induced by the oestrogen component (Wynn and Doar, 1966) . More recently the finding of raised blood pyruvate levels in obese subjects (Doar et al., 1968) has drawn our attention to certain metabolic similarities shared by obese subjects and these taking oral contraceptive therapy. The present study evaluates the plasma glucose and blood pyruvate levels after oral glucose tolerance test in non-obese and obese women (controls) compared with similar women receiving oestrogenprogestogen therapy or glucocorticoid drugs.
Subjects
Details of control subjects and subjects receiving oral contraceptive or glucocorticoid therapy are shown in Table I . The indications for glucocorticoid therapy were uveitis, asthma, or rheumatoid arthritis. Subjects received prednisone or prednisolone (mean daily dose 10 mg., range 4 to 25 mg.). No subject was taking any drug known to affect carbohydrate or intermediary metabolism, excepting oral contraceptives and glucocorticoid drugs. All women were advised to consume 200 g. of carbohydrate for three days before their test. Known diabetics were excluded. Subjects were subsequently diagnosed as diabetic if they had both fasting hyperglycaemia (plasma glucose level > 102 mg./100 ml.) and an abnormal oral glucose tolerance area (see below). These subjects were excluded from all three groups.
Procedures and Methods
Oral glucose tolerance tests were carried out as previously described (Wynn and Doar, 1966) , a glucose load of 1 g./kg. body weight being used. Plasma glucose was measured by an automated glucose oxidase method (Cramp, 1967) and blood pyruvate by an automated enzymatic fluorimetric technique (Cramp, 1968) . Plasma glucose and blood pyruvate levels in response to glucose tolerance tests were assessed as the mean levels at each time interval. Individual plasma glucose curves were also assessed as the total area between the curve and the abscissa, calculated in arbitrary units, assuming straight lines between successive points. We currently regard 800 units as the upper limit of normal in non-obese women aged 20 to 40. Standard statistical methods were used, including Student's t test and Snedecor's F test.
Results

Plasma Glucose Levels
The mean fasting plasma glucose level was similar in nonobese and obese control, glucocorticoid, and oral contraceptive groups (Tables II and 111 ). Oral glucose tolerance, however, was relatively impaired in the obese control and non-obese glucocorticoid and oral contraceptive groups. A more pronounced deterioration of oral glucose tolerance was evident in the obese glucocorticoid and oral contraceptive groups (Tables II and III) , though only the latter achieved statistical significance, probably because of the small numbers of subjects in the glucocorticoid group.
Blood Pyruvate Levels
Similar rises in the mean fasting blood pyruvate level were found in the control obese and non-obese oral contraceptive and glucocorticoid groups compared with that of the control non-obese group (Tables IV and V) . Mean blood pyruvate -1----~~~~~~~ I_ levels were also much higher in these three groups after oral glucose administration. Mean blood pyruvate levels were even higher in the obese glucocorticoid and obese oral contraceptive groups (Tables IV and V) . The variances of blood in three metabolic situations-namely, obesity, oral contraceptive therapy, and glucocorticoid administration. The combination of obesity and glucocorticoid or oral contraceptive therapy exerted an additive effect on the impairment of glucose pyruvate levels of the control obese and non-obese glucocorticoid and non-obese oral contraceptive groups were significantly greater than those of the non-obese control group (Tables VI and VII) . Controlnon The response of the plasma glucose and blood pyruvate levels to glucose tolerance tests in the obese control and nonobese glucocorticoid and oral contraceptive groups showed striking similarities (see Figs. 1 and 2 overleaf) .
The present study has shown oral glucose tolerance to be relatively impaired, in the absence of fasting hyperglycaemia, tolerance. Obesity was also associated with raised blood pyruvate levels in control, glucocorticoid, and oral contraceptive groups of subjects. Glucose tolerance tests revealed striking similarities of plasma glucose and blood pyruvate levels in the obese control, non-obese oral contraceptive, and nonobese glucocorticoid groups of subjects. These observations are compatible with, but do not prove, the hypothesis that the abnormalities of plasma glucose and blood pyruvate levels in obesity and during oral contraceptive or glucocorticoid administration to non-obese subjects result from a common mechanism. We have suggested that the liver may be exposed to glucocorticoid excess in all three situations .
Though the raised plasma cortisol levels during oestrogen administration are mainly due to an increase of protein-bound cortisol, thought to be biologically inactive (Matsui and Plager, 1966) , recent work (Keller et al., 1969) suggests that this fraction may exert biological activity in certain tissues with protein-permeable vascular beds such as the liver. Keller et al. (1969) found that the activity of alanine aminotransferase was increased by previous treatment with corticosterone in both rat liver and pancreas tissue. When the plasma -corticosterone level was raised by oestrogen treatment, however, only the hepatic enzyme responded with increased activity. Furthermore, recent studies have indicated that the non-protein-bound plasma cortisol kvels are also increased during oestrogen therapy (Burke, 1969; Sandberg et al., 1969 progestogen therapy administered singly, but the available evidence indicates that the oestrogen component alone can account for the abnormalities of glucose tolerance (Javier et al., 1968; Goldman et al., 1968; Goldman and Ovadia, 1969) and blood pyruvate levels oestrogen-progestogen therapy. Circulating plasma cortisol levels are usually normal in obesity, but the cortisol production rate is often increased (Schteingart and Conn, 1965) . The hepatic clearance of cortisol is therefore increased and a local effect on hepatic glucose and pyruvate handling is possible. Obesity (Perley and Kipnis, 1966a) , oral contraceptive therapy , and glucocorticoid therapy (Perley and Kipnis, 1966b) are associated with raised plasma insulin levels in response to a glucose tolerance test. Since plasma glucose levels are also increased, it appears that there is increased resistance in one or more tissues to the actions of insulin. Studies of pyruvate metabolism using a sodium L (-+) lactate infusion technique have suggested that the abnormally raised blood pyruvate levels in obesity, and during glucocorticoid or oral contraceptive therapy, are caused by an increased proportion of the .glucose load passing down the glycolytic pathway to pyruvate rather than an impaired rate of removal of this metabolite Doar and Cramp, in preparation) . If the peripheral insulin resistance referred to above were to affect non-glycolytic pathways of glucose metabolism more than the glycolytic pathway, the combination of raised plasma glucose and insulin levels could result in an increased rate of formation of pyruvate from glucose in certain tissues.
The increased variance of blood pyruvate levels in response to a glucose tolerance test in the non-obese oral contraceptive and glucocorticoid groups may reflect the heterogeneous nature of the drug therapy. The type of drug and dose and duration of therapy varied widely within each group. We have been unable to detect, however, a relation between any one of these factors and the change of blood pyruvate levels during oral contraceptive therapy . The increased variance in the control obese group may be due to the greater range of degree of obesity of these subjects compared with that of the non-obese group, since we have previously found a significant correlation (r=032, P<001) between the fasting blood pyruvate level and the degree of obesity in non-diabetic women (Doar et al., 1968) . The abnormalities of blood pyruvate levels in response to a glucose tolerance test reported here differ from those observed in maturity-onset diabetes mellitus. In a detailed study (Doar et al., in preparation) we have found no influence of diabetes mellitus (either maturity-onset or insulin-requiring) on the fasting blood pyruvate level. The mean fasting blood pyruvate level, however, was higher in obese than non-obese diabetic subjects. Mean blood pyruvate levels were higher in both obese and non-obese maturity-onset diabetic subjects during the later stages of the test compared with mean blood pyruvate levels in non-diabetic subjects of similar degree of obesity.
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